[go: up one dir, main page]

HRP20211225T1 - SULPHONILUREAS AND RELATED COMPOUNDS AND THEIR USE - Google Patents

SULPHONILUREAS AND RELATED COMPOUNDS AND THEIR USE Download PDF

Info

Publication number
HRP20211225T1
HRP20211225T1 HRP20211225TT HRP20211225T HRP20211225T1 HR P20211225 T1 HRP20211225 T1 HR P20211225T1 HR P20211225T T HRP20211225T T HR P20211225TT HR P20211225 T HRP20211225 T HR P20211225T HR P20211225 T1 HRP20211225 T1 HR P20211225T1
Authority
HR
Croatia
Prior art keywords
disease
alkyl
independently selected
group
compound according
Prior art date
Application number
HRP20211225TT
Other languages
Croatian (hr)
Inventor
Luke O'neill
Matthew Cooper
Avril Robertson
Kate SCHRODER
Original Assignee
The University Of Queensland
The Provost, Fellows, Foundation Scholars, and the other members of Board, of the College of the Holy& Undiv. Trinity of Queen Elizabeth near Dublin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56691944&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20211225(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from AU2015900507A external-priority patent/AU2015900507A0/en
Application filed by The University Of Queensland, The Provost, Fellows, Foundation Scholars, and the other members of Board, of the College of the Holy& Undiv. Trinity of Queen Elizabeth near Dublin filed Critical The University Of Queensland
Publication of HRP20211225T1 publication Critical patent/HRP20211225T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/52—Y being a hetero atom
    • C07C311/54—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea
    • C07C311/56—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/52—Y being a hetero atom
    • C07C311/54—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea
    • C07C311/57—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/60—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings having nitrogen atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/38—2-Pyrrolones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C07D213/71—Sulfur atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/18—Ring systems of four or more rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/08—1,2,5-Oxadiazoles; Hydrogenated 1,2,5-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/12—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/64—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/16—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/18—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted otherwise than in position 3 or 7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/60—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with aryl radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
    • C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)

Claims (20)

1. Spoj formule (I), ili njegova farmaceutski prihvatljiva sol ili solvat: [image] pri čemu je W odabran od O, S i Se; J je odabran od S i Se; R1 je odabran iz skupine koja se sastoji od 5-eročlanog i 6-eročlanog heterociklila, koji svi mogu biti po izboru supstituirani, pri čemu je bilo koji izborni supstituent neovisno odabran iz skupine koju čine C1-10 alkil; C3-6 cikloalkil; hidroksialkil; C1-10 alkoksi; C2-10 alkenil; C2-10 alkinil; C6-C12 aril; ariloksi; heteroaril; heterociklil; halo; hidroksil; halogenirani alkil; amino; alkilamino; arilamino; acil; amido; CN; NO2; N3; CH20H; CONH2; CONR24R25; CO2R24; CH2OR24; NHCOR24; NHCO2R24; C1-3 alkiltio; sulfat; sulfonska kiselina; sulfonatni esteri; fosfonska kiselina; fosfat; fosfonat; mono-, di- ili trifosfatni esteri; tritil; monometoksitrtil; R24SO; R24S02; CF3S; CF3SO2; i trialkilsilil; pri čemu su R24 i R25 svaki neovisno odabrani između H i C1-10 alkila; R2 je odabran između 2,6-dialkilfenil, 2,6-dialkil-4-halofenil, 2,6-dicikloalkilfenil, 2,6-dicikloalkil-4-halofenil i: [image] pri čemu se svaka incidencija Y neovisno bira između C, N, S i O, koji se prema potrebi mogu supstituirati, pri čemu se bilo koji izborni supstituent neovisno bira iz skupine koja se sastoji od C1-10 alkil; C3-6 cikloalkil; hidroksialkil; C1-10 alkoksi; C2-10 alkenil; C2-10 alkinil; C6-C12 aril; ariloksi; heteroaril; heterociklil; halo; hidroksil; halogenirani alkil; amino; alkilamino; arilamino; acil; amido; CN; NO2; N3; CH20H; CONH2; CONR24R25; CO2R24; CH2OR24; NHCOR24; NHCO2R24; C1-3 alkiltio; sulfat; sulfonska kiselina; sulfonatni esteri; fosfonska kiselina; fosfat; fosfonat; mono-, di- ili trifosfatni esteri; tritil; monometoksitrtil; R24SO; R24S02; CF3S; CF3SO2; i trialkilsilil; pri čemu su R24 i R25 svaki neovisno odabrani između H i C1-10 alkila; R5 je odabran iz skupine koju čine vodik, halo, cijano, amid, sulfonamid, acil, hidroksil, C1-C6 alkil, C1-C6 haloalkil, C3-C5 ciloalkil i C1-C6 alkoksi, koje sve skupine mogu biti po želji supstituirane, prema potrebi, s halo, cijano ili C1-C6 alkoksi; i oba R1 su izravno vezana za J, a R2 je izravno vezan za susjedni dušik, preko atoma ugljika.1. Compound of formula (I), or its pharmaceutically acceptable salt or solvate: [image] wherein W is selected from O, S and Se; J is selected from S and Se; R 1 is selected from the group consisting of 5-membered and 6-membered heterocyclyl, all of which may be optionally substituted, wherein any optional substituent is independently selected from the group consisting of C 1-10 alkyl; C3-6 cycloalkyl; hydroxyalkyl; C1-10 Alkoxy; C2-10 alkenyl; C2-10 alkynyl; C6-C12 aryl; aryloxy; heteroaryl; heterocyclyl; halo; hydroxyl; halogenated alkyl; amino; alkylamino; arylamino; acyl; amido; CN; NO2; N3; CH2OH; CONH2; CONR24R25; CO2R24; CH2OR24; NHCOR24; NHCO2R24; C1-3 alkylthio; sulfate; sulfonic acid; sulfonate esters; phosphonic acid; phosphate; phosphonate; mono-, di- or triphosphate esters; trityl; monomethoxytrtyl; R24SO; R24S02; CF3S; CF3SO2; and trialkylsilyl; wherein R 24 and R 25 are each independently selected from H and C 1-10 alkyl; R 2 is selected from 2,6-dialkylphenyl, 2,6-dialkyl-4-halophenyl, 2,6-dicycloalkylphenyl, 2,6-dicycloalkyl-4-halophenyl and: [image] wherein each incidence of Y is independently selected from C, N, S, and O, which may optionally be substituted, wherein any optional substituent is independently selected from the group consisting of C1-10 alkyl; C3-6 cycloalkyl; hydroxyalkyl; C1-10 Alkoxy; C2-10 alkenyl; C2-10 alkynyl; C6-C12 aryl; aryloxy; heteroaryl; heterocyclyl; halo; hydroxyl; halogenated alkyl; amino; alkylamino; arylamino; acyl; amido; CN; NO2; N3; CH2OH; CONH2; CONR24R25; CO2R24; CH2OR24; NHCOR24; NHCO2R24; C1-3 alkylthio; sulfate; sulfonic acid; sulfonate esters; phosphonic acid; phosphate; phosphonate; mono-, di- or triphosphate esters; trityl; monomethoxytrtyl; R24SO; R24S02; CF3S; CF3SO2; and trialkylsilyl; wherein R 24 and R 25 are each independently selected from H and C 1-10 alkyl; R5 is selected from the group consisting of hydrogen, halo, cyano, amide, sulfonamide, acyl, hydroxyl, C1-C6 alkyl, C1-C6 haloalkyl, C3-C5 cycloalkyl and C1-C6 alkoxy, all of which groups may be optionally substituted, optionally, with halo, cyano or C1-C6 alkoxy; and both R1 are directly attached to J, and R2 is directly attached to the adjacent nitrogen, via a carbon atom. 2. Spoj u skladu s patentnim zahtjevom 1, naznačen time što R1 je 6-člani heterociklil, koji može biti prema potrebi supstituiran, pri čemu je bilo koji izborni supstituent neovisno odabran iz skupine koja se sastoji od C1-10 alkil; C3-6 cikloalkil; hidroksialkil; C1-10 alkoksi; C2-10 alkenil; C2-10 alkinil; C6-C12 aril; ariloksi; heteroaril; heterociklil; halo; hidroksil; halogenirani alkil; amino; alkilamino; arilamino; acil; amido; CN; NO2; N3; CH2OH; CONH2; CONR24R25; CO2R24; CH2OR24; NHCOR24; NHCO2R24; C1-3 alkiltio; sulfat; sulfonska kiselina; sulfonatni esteri; fosfonska kiselina; fosfat; fosfonat; mono-, di- ili trifosfatni esteri; tritil; monometoksitrtil; R24SO; R24SO2; CF3S; CF3SO2; i trialkilsilil; pri čemu su R24 i R25 svaki neovisno odabrani između H i C1-10 alkila.2. A compound according to claim 1, characterized in that R1 is a 6-membered heterocyclyl, which can be optionally substituted, wherein any optional substituent is independently selected from the group consisting of C1-10 alkyl; C3-6 cycloalkyl; hydroxyalkyl; C1-10 Alkoxy; C2-10 alkenyl; C2-10 alkynyl; C6-C12 aryl; aryloxy; heteroaryl; heterocyclyl; halo; hydroxyl; halogenated alkyl; amino; alkylamino; arylamino; acyl; amido; CN; NO2; N3; CH2OH; CONH2; CONR24R25; CO2R24; CH2OR24; NHCOR24; NHCO2R24; C1-3 alkylthio; sulfate; sulfonic acid; sulfonate esters; phosphonic acid; phosphate; phosphonate; mono-, di- or triphosphate esters; trityl; monomethoxytrtyl; R24SO; R24SO2; CF3S; CF3SO2; and trialkylsilyl; wherein R 24 and R 25 are each independently selected from H and C 1-10 alkyl. 3. Spoj prema bilo kojem od prethodnih zahtjeva, naznačen time, da je R1 potpuno zasićeni heterociklil, koji može biti prema potrebi supstituiran, pri čemu je bilo koji izborni supstituent neovisno odabran iz skupine koja se sastoji od C1-10 alkil; C3-6 cikloalkil; hidroksialkil; C1-10 alkoksi; C2-10 alkenil; C2-10 alkinil; C6-C12 aril; ariloksi; heteroaril; heterociklil; halo; hidroksil; halogenirani alkil; amino; alkilamino; arilamino; acil; amido; CN; NO2; N3; CH2OH; CONH2; CONR24R25; CO2R24; CH2OR24; NHCOR24; NHCO2R24; C1-3 alkiltio; sulfat; sulfonska kiselina; sulfonatni esteri; fosfonska kiselina; fosfat; fosfonat; mono-, di- ili trifosfatni esteri; tritil; monometoksitrtil; R24SO; R24SO2; CF3S; CF3SO2; i trialkilsilil; pri čemu su R24 i R25 svaki neovisno odabrani između H i C1-10 alkila.3. A compound according to any of the preceding claims, characterized in that R1 is fully saturated heterocyclyl, which may be optionally substituted, wherein any optional substituent is independently selected from the group consisting of C1-10 alkyl; C3-6 cycloalkyl; hydroxyalkyl; C1-10 Alkoxy; C2-10 alkenyl; C2-10 alkynyl; C6-C12 aryl; aryloxy; heteroaryl; heterocyclyl; halo; hydroxyl; halogenated alkyl; amino; alkylamino; arylamino; acyl; amido; CN; NO2; N3; CH2OH; CONH2; CONR24R25; CO2R24; CH2OR24; NHCOR24; NHCO2R24; C1-3 alkylthio; sulfate; sulfonic acid; sulfonate esters; phosphonic acid; phosphate; phosphonate; mono-, di- or triphosphate esters; trityl; monomethoxytrtyl; R24SO; R24SO2; CF3S; CF3SO2; and trialkylsilyl; wherein R 24 and R 25 are each independently selected from H and C 1-10 alkyl. 4. Spoj prema bilo kojem od prethodnih zahtjeva, naznačen time, da R1 je dušikov heterociklil, koji može biti prema potrebi supstituiran, pri čemu je bilo koji izborni supstituent neovisno odabran iz skupine koja se sastoji od C1-10 alkil; C3-6 cikloalkil; hidroksialkil; C1-10 alkoksi; C2-10 alkenil; C2-10 alkinil; C6-C12 aril; ariloksi; heteroaril; heterociklil; halo; hidroksil; halogenirani alkil; amino; alkilamino; arilamino; acil; amido; CN; NO2; N3; CH2OH; CONH2; CONR24R25; CO2R24; CH2OR24; NHCOR24; NHCO2R24; C1-3 alkiltio; sulfat; sulfonska kiselina; sulfonatni esteri; fosfonska kiselina; fosfat; fosfonat; mono-, di- ili trifosfatni esteri; tritil; monometoksitrtil; R24SO; R24SO2; CF3S; CF3SO2; i trialkilsilil; pri čemu su R24 i R25 svaki neovisno odabrani između H i C1-10 alkila.4. A compound according to any of the preceding claims, characterized in that R1 is nitrogen heterocyclyl, which may be optionally substituted, wherein any optional substituent is independently selected from the group consisting of C1-10 alkyl; C3-6 cycloalkyl; hydroxyalkyl; C1-10 Alkoxy; C2-10 alkenyl; C2-10 alkynyl; C6-C12 aryl; aryloxy; heteroaryl; heterocyclyl; halo; hydroxyl; halogenated alkyl; amino; alkylamino; arylamino; acyl; amido; CN; NO2; N3; CH2OH; CONH2; CONR24R25; CO2R24; CH2OR24; NHCOR24; NHCO2R24; C1-3 alkylthio; sulfate; sulfonic acid; sulfonate esters; phosphonic acid; phosphate; phosphonate; mono-, di- or triphosphate esters; trityl; monomethoxytrtyl; R24SO; R24SO2; CF3S; CF3SO2; and trialkylsilyl; wherein R 24 and R 25 are each independently selected from H and C 1-10 alkyl. 5. Spoj prema bilo kojem od prethodnih zahtjeva, naznačen time, da je R1 odabran iz skupine koju čine tetrahidrofuran, tetrahidropiran, piran, pirolidin, morfolin, piperazin i piperidin, koji svi mogu biti prema potrebi supstituirani, pri čemu je bilo koji izborni supstituent neovisno odabran iz skupine koju čine C1-10 alkil; C3-6 cikloalkil; hidroksialkil; C1-10 alkoksi; C2-10 alkenil; C2-10 alkinil; C6-C12 aril; ariloksi; heteroaril; heterociklil; halo; hidroksil; halogenirani alkil; amino; alkilamino; arilamino; acil; amido; CN; NO2; N3; CH2OH; CONH2; CONR24R25; CO2R24; CH2OR24; NHCOR24; NHCO2R24;; C1-3 alkiltio; sulfat; sulfonska kiselina; sulfonatni esteri; fosfonska kiselina; fosfat; fosfonat; mono-, di- ili trifosfatni esteri; tritil; monometoksitrtil; R24SO; R24SO2; CF3S; CF3SO2; i trialkilsilil; pri čemu su R24 i R25 svaki neovisno odabrani između H i C1-10 alkila.5. A compound according to any of the preceding claims, characterized in that R1 is selected from the group consisting of tetrahydrofuran, tetrahydropyran, pyran, pyrrolidine, morpholine, piperazine and piperidine, all of which may be optionally substituted, wherein any optional substituent is independently selected from the group consisting of C1-10 alkyl; C3-6 cycloalkyl; hydroxyalkyl; C1-10 Alkoxy; C2-10 alkenyl; C2-10 alkynyl; C6-C12 aryl; aryloxy; heteroaryl; heterocyclyl; halo; hydroxyl; halogenated alkyl; amino; alkylamino; arylamino; acyl; amido; CN; NO2; N3; CH2OH; CONH2; CONR24R25; CO2R24; CH2OR24; NHCOR24; NHCO2R24;; C1-3 alkylthio; sulfate; sulfonic acid; sulfonate esters; phosphonic acid; phosphate; phosphonate; mono-, di- or triphosphate esters; trityl; monomethoxytrtyl; R24SO; R24SO2; CF3S; CF3SO2; and trialkylsilyl; wherein R 24 and R 25 are each independently selected from H and C 1-10 alkyl. 6. Spoj prema bilo kojem od prethodnih zahtjeva, naznačen time, da je R1 odabran iz skupine koju čine tetrahidrofuran, tetrahidropiran, pirolidin, morfolin, piperazin i piperidin, koji svi mogu biti prema potrebi supstituirani, pri čemu je bilo koji izborni supstituent neovisno odabran iz skupine koju čine C1-10 alkil; C3-6 cikloalkil; hidroksialkil; C1-10 alkoksi; C2-10 alkenil; C2-10 alkinil; C6-C12 aril; ariloksi; heteroaril; heterociklil; halo; hidroksil; halogenirani alkil; amino; alkilamino; arilamino; acil; amido; CN; NO2; N3; CH2OH; CONH2; CONR24R25; CO2R24; CH2OR24; NHCOR24; NHCO2R24; C1-3 alkiltio; sulfat; sulfonska kiselina; sulfonatni esteri; fosfonska kiselina; fosfat; fosfonat; mono-, di- ili trifosfatni esteri; tritil; monometoksitrtil; R24SO; R24SO2; CF3S; CF3SO2; i trialkilsilil; pri čemu su R24 i R25 svaki neovisno odabrani između H i C1-10 alkila.6. A compound according to any of the preceding claims, characterized in that R1 is selected from the group consisting of tetrahydrofuran, tetrahydropyran, pyrrolidine, morpholine, piperazine and piperidine, all of which may be optionally substituted, wherein any optional substituent is independently selected from the group consisting of C1-10 alkyl; C3-6 cycloalkyl; hydroxyalkyl; C1-10 Alkoxy; C2-10 alkenyl; C2-10 alkynyl; C6-C12 aryl; aryloxy; heteroaryl; heterocyclyl; halo; hydroxyl; halogenated alkyl; amino; alkylamino; arylamino; acyl; amido; CN; NO2; N3; CH2OH; CONH2; CONR24R25; CO2R24; CH2OR24; NHCOR24; NHCO2R24; C1-3 alkylthio; sulfate; sulfonic acid; sulfonate esters; phosphonic acid; phosphate; phosphonate; mono-, di- or triphosphate esters; trityl; monomethoxytrtyl; R24SO; R24SO2; CF3S; CF3SO2; and trialkylsilyl; wherein R 24 and R 25 are each independently selected from H and C 1-10 alkyl. 7. Spoj prema bilo kojem od prethodnih zahtjeva, naznačen time, da je R1 odabran iz skupine koju čine pirolidin, piperazin i piperidin, a svi oni mogu biti prema potrebi supstituirani, pri čemu je bilo koji izborni supstituent neovisno odabran iz skupine koju čine C1-10 alkil; C3-6 cikloalkil; hidroksialkil; C1-10 alkoksi; C2-10 alkenil; C2-10 alkinil; C6-C12 aril; ariloksi; heteroaril; heterociklil; halo; hidroksil; halogenirani alkil; amino; alkilamino; arilamino; acil; amido; CN; NO2; N3; CH2OH; CONH2; CONR24R25; CO2R24; CH2OR24; NHCOR24; NHCO2R24; C1-3 alkiltio; sulfat; sulfonska kiselina; sulfonatni esteri; fosfonska kiselina; fosfat; fosfonat; mono-, di- ili trifosfatni esteri; tritil; monometoksitrtil; R24SO; R24SO2; CF3S; CF3SO2; i trialkilsilil; pri čemu su R24 i R25 svaki neovisno odabrani između H i C1-10 alkila.7. A compound according to any of the preceding claims, characterized in that R1 is selected from the group consisting of pyrrolidine, piperazine and piperidine, all of which may be optionally substituted, wherein any optional substituent is independently selected from the group consisting of C1 -10 alkyl; C3-6 cycloalkyl; hydroxyalkyl; C1-10 Alkoxy; C2-10 alkenyl; C2-10 alkynyl; C6-C12 aryl; aryloxy; heteroaryl; heterocyclyl; halo; hydroxyl; halogenated alkyl; amino; alkylamino; arylamino; acyl; amido; CN; NO2; N3; CH2OH; CONH2; CONR24R25; CO2R24; CH2OR24; NHCOR24; NHCO2R24; C1-3 alkylthio; sulfate; sulfonic acid; sulfonate esters; phosphonic acid; phosphate; phosphonate; mono-, di- or triphosphate esters; trityl; monomethoxytrtyl; R24SO; R24SO2; CF3S; CF3SO2; and trialkylsilyl; wherein R 24 and R 25 are each independently selected from H and C 1-10 alkyl. 8. Spoj prema bilo kojem od zahtjeva 1, 2, 3, 5 ili 6, naznačen time, da je R1 odabran iz skupine koja se sastoji od: [image] i u kombinaciji sa svakom takvom R1 skupinom, R2 se neovisno bira iz skupine koju čine: [image] [image] [image] [image] 8. A compound according to any one of claims 1, 2, 3, 5 or 6, characterized in that R1 is selected from the group consisting of: [image] and in combination with each such R1 group, R2 is independently selected from the group consisting of: [image] [image] [image] [image] 9. Spoj prema bilo kojem od prethodnih zahtjeva, naznačen time, da se R2 bira između: [image] pri čemu su Y i R5 definirani u bilo kojem od prethodnih zahtjeva.9. A compound according to any of the preceding claims, characterized in that R2 is selected from: [image] wherein Y and R5 are as defined in any of the preceding claims. 10. Spoj prema bilo kojem od prethodnih zahtjeva, naznačen time, da se R2 bira između: [image] pri čemu je svaka incidencija Y ugljik, a R5 je vodik ili halo.10. A compound according to any of the preceding claims, characterized in that R2 is selected from: [image] wherein each occurrence of Y is carbon and R 5 is hydrogen or halo. 11. Spoj prema bilo kojem od prethodnih zahtjeva, naznačen time, da je R2 odabran između supstituiranog ili hidrogeniranog indacena, 2,6-dialkilfenila, 2,6-dialkil-4-halofenila, 2,6-dicikloalkilfenila i 2,6-dicikloalkil-4-halofenila.11. A compound according to any of the preceding claims, characterized in that R2 is selected from substituted or hydrogenated indacene, 2,6-dialkylphenyl, 2,6-dialkyl-4-halophenyl, 2,6-dicycloalkylphenyl and 2,6-dicycloalkyl -4-halophenyl. 12. Spoj prema bilo kojem od prethodnih zahtjeva, naznačen time, da je R2 odabran između heksahidroindacena, 2,6-diizopropilfenil, 2,6-diizopropil-4-klorofenil, 2,6-diciklopropilfenil i 2,6-diciklopropil-4-klorofenila.12. A compound according to any of the preceding claims, characterized in that R2 is selected from hexahydroindacene, 2,6-diisopropylphenyl, 2,6-diisopropyl-4-chlorophenyl, 2,6-dicyclopropylphenyl and 2,6-dicyclopropyl-4- chlorophenyl. 13. Spoj prema bilo kojem od prethodnih zahtjeva, naznačen time, da je J atom sumpora.13. A compound according to any of the preceding claims, characterized in that J is a sulfur atom. 14. Spoj prema bilo kojem od prethodnih zahtjeva, naznačen time, da je W atom kisika.14. A compound according to any of the preceding claims, characterized in that W is an oxygen atom. 15. Spoj prema bilo kojem od prethodnih zahtjeva, naznačen time, da je spoj spoj formule (Ia), (Ib) ili (Ic), ili njegova farmaceutski prihvatljiva sol ili solvat: [image] pri čemu je R1 definiran u bilo kojem od prethodnih zahtjeva.15. A compound according to any of the preceding claims, characterized in that the compound is a compound of formula (Ia), (Ib) or (Ic), or a pharmaceutically acceptable salt or solvate thereof: [image] wherein R 1 is as defined in any of the preceding claims. 16. Spoj prema bilo kojem od zahtjeva 1-3, 5-6 ili 8-15, naznačen time, da je spoj odabran iz skupine koju čine: [image] i njihove farmaceutski prihvatljive soli i solvati.16. A compound according to any one of claims 1-3, 5-6 or 8-15, characterized in that the compound is selected from the group consisting of: [image] and pharmaceutically acceptable salts and solvates thereof. 17. Farmaceutski pripravak, naznačen time što sadrži spoj prema bilo kojem od zahtjeva 1 do 16, ili njegova farmaceutski prihvatljiva sol ili solvat, i farmaceutski prihvatljiv nosač, razrjeđivač i/ili pomoćnu tvar.17. Pharmaceutical preparation, characterized in that it contains a compound according to any one of claims 1 to 16, or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier, diluent and/or auxiliary substance. 18. Spoj ili farmaceutski prihvatljiva sol ili solvat prema bilo kojem od zahtjeva 1 do 16, naznačen time, da se koristi u medicini.18. A compound or a pharmaceutically acceptable salt or solvate according to any one of claims 1 to 16, characterized in that it is used in medicine. 19. Spoj ili farmaceutski prihvatljiva sol ili solvat prema bilo kojem od zahtjeva 1 do 16, naznačen time, da se koristi u liječenju ili prevenciji navedenih: (a) bolest, poremećaj ili stanje imunološkog sustava; i/ili (b) upalna bolest, poremećaj ili stanje ili autoimuna bolest, poremećaj ili stanje; i/ili (c) bolest, poremećaj ili stanje kože; i/ili (d) bolest, poremećaj ili stanje kardiovaskularnog sustava; i/ili (e) rak, tumor ili drugi zloćudni tumor; i/ili (f) bolest, poremećaj ili stanje bubrežnog sustava; i/ili (g) bolest, poremećaj ili stanje gastrointestinalnog trakta; i/ili (h) bolest, poremećaj ili stanje dišnog sustava; i/ili (i) bolest, poremećaj ili stanje endokrinog sustava; i/ili (j) bolest, poremećaj ili stanje središnjeg živčanog sustava (CNS); i/ili (k) bolest, poremećaj ili stanje odabrano iz skupine koja se sastoji od konstitutivne upale, uključujući periodične sindrome povezane s kriopirinom (CAPS): Muckle-Wellsov sindrom (MWS), obiteljski hladni autoinflamatorni sindrom (FCAS) i multisustavna upalna bolest s novorođenčetom (NOMID); uključujući autoinflamatorne bolesti: obiteljska mediteranska groznica (FMF), periodični sindrom povezan s TNF receptorima (TRAPS), nedostatak mevalonate kinaze (MKD), hiperimunoglobulinemija D i sindrom periodične groznice (HIDS), nedostatak antagonista receptora za interleukin 1 (DIRA), Majeedov sindrom, piogeni artritis, gangrenozna piodermija i akne (PAPA), haploinsuficijencija A20 (HA20), dječji granulomatozni artritis (PGA), nedostatak protutijela povezan s PLCG2 i imunološka disregulacija (PLAID), autoinflamacija povezana s PLCG2, nedostatak protutijela i imunološka disregulacija , sideroblastična anemija s imunodeficijencijom B-stanica, periodična groznica i zastoj u razvoju (SIFD); Sweetov sindrom, kronični nebakterijski osteomijelitis (CNO), kronični recidivni multifokalni osteomijelitis (CRMO) i sinovitis, akne, pustuloza, hiperostoza, sindrom osteitisa (SAPHO); autoimune bolesti, uključujući multiple sklerozu (MS), dijabetes tipa 1, psorijazu, reumatoidni artritis, Behcetovu bolest, Sjogrenov sindrom i Schnitzlerov sindrom; respiratorne bolesti, uključujući kronični opstruktivni plućni poremećaj (KOPB), steroidno rezistentna astma, azbestoza, silikoza i cistična fibroza; bolesti središnjeg živčanog sustava, uključujući Parkinsonovu bolest, Alzheimerovu bolest, bolest motornih neurona, Huntingtonovu bolest, cerebralnu malariju i ozljedu mozga od pneumokoknog meningitisa; metaboličke bolesti, uključujući dijabetes tipa 2, aterosklerozu, pretilost, giht, pseudo-giht; očne bolesti, uključujući one očnog epitela, starosnu degeneraciju makule (AMD), infekciju rožnice, uveitis i suho oko; bolesti bubrega, uključujući kroničnu bolest bubrega, oksalatnu nefropatiju i dijabetičku nefropatiju; bolesti jetre, uključujući bezalkoholni steatohepatitis i alkoholnu bolest jetre; upalne reakcije na koži, uključujući kontaktnu preosjetljivost i opekline; upalne reakcije u zglobovima, uključujući osteoartritis, sistemski juvenilni idiopatski artritis, Stillova bolest kod odraslih, recidivirajući polihondritis; virusne infekcije, uključujući alfa virus, uključujući Chikungunya i rijeku Ross, i flavivirus, uključujući denga i zika viruse, gripu, HIV; hidradenitis suppurativa (HS) i druge kožne bolesti koje uzrokuju ciste; karcinomi, uključujući metastaze raka pluća, karcinom gušterače, rak želuca, mijelodisplastični sindrom, leukemija; polimiozitis; moždani udar; infarkt miokarda; Kalemljenje naspram bolesti domaćina; hipertenzija; kolitis; infekcija helminthima; bakterijska infekcija; aneurizam trbušne aorte; zarastanje rana; depresija, psihološki stres; perikarditis, uključujući Dresslerov sindrom, reperfuzijsku ozljedu ishemije i bilo koju bolest kod koje je utvrđeno da pojedinac nosi zametnu liniju ili somatsku netihu mutaciju u NLRP3.19. A compound or a pharmaceutically acceptable salt or solvate according to any one of claims 1 to 16, characterized in that it is used in the treatment or prevention of the following: (a) disease, disorder or condition of the immune system; and/or (b) an inflammatory disease, disorder or condition or an autoimmune disease, disorder or condition; and/or (c) a disease, disorder or condition of the skin; and/or (d) disease, disorder or condition of the cardiovascular system; and/or (e) cancer, tumor or other malignant tumor; and/or (f) disease, disorder or condition of the renal system; and/or (g) disease, disorder or condition of the gastrointestinal tract; and/or (h) disease, disorder or condition of the respiratory system; and/or (i) disease, disorder or condition of the endocrine system; and/or (j) central nervous system (CNS) disease, disorder or condition; and/or (k) a disease, disorder or condition selected from the group consisting of constitutive inflammation, including cryopyrin-associated periodic syndromes (CAPS): Muckle-Wells syndrome (MWS), familial cold autoinflammatory syndrome (FCAS), and multisystem inflammatory disease of the newborn ( NOMID); including autoinflammatory diseases: familial Mediterranean fever (FMF), TNF receptor-associated periodic syndrome (TRAPS), mevalonate kinase deficiency (MKD), hyperimmunoglobulinemia D and periodic fever syndrome (HIDS), interleukin 1 receptor antagonist (DIRA) deficiency, Majeed syndrome , pyogenic arthritis, pyoderma gangrenosum and acne (PAPA), haploinsufficiency A20 (HA20), pediatric granulomatous arthritis (PGA), PLCG2-associated antibody deficiency and immune dysregulation (PLAID), PLCG2-associated autoinflammation, antibody deficiency and immune dysregulation , sideroblastic anemia with B-cell immunodeficiency, periodic fever and developmental delay (SIFD); Sweet's syndrome, chronic nonbacterial osteomyelitis (CNO), chronic recurrent multifocal osteomyelitis (CRMO) and synovitis, acne, pustulosis, hyperostosis, osteitis syndrome (SAPHO); autoimmune diseases, including multiple sclerosis (MS), type 1 diabetes, psoriasis, rheumatoid arthritis, Behcet's disease, Sjogren's syndrome and Schnitzler's syndrome; respiratory diseases, including chronic obstructive pulmonary disorder (COPD), steroid-resistant asthma, asbestosis, silicosis and cystic fibrosis; diseases of the central nervous system, including Parkinson's disease, Alzheimer's disease, motor neuron disease, Huntington's disease, cerebral malaria and brain injury from pneumococcal meningitis; metabolic diseases, including type 2 diabetes, atherosclerosis, obesity, gout, pseudo-gout; eye diseases, including those of the eye epithelium, age-related macular degeneration (AMD), corneal infection, uveitis, and dry eye; kidney diseases, including chronic kidney disease, oxalate nephropathy and diabetic nephropathy; liver diseases, including non-alcoholic steatohepatitis and alcoholic liver disease; inflammatory skin reactions, including contact hypersensitivity and burns; inflammatory reactions in the joints, including osteoarthritis, systemic juvenile idiopathic arthritis, Still's disease in adults, relapsing polychondritis; viral infections, including alpha virus, including Chikungunya and Ross River, and flavivirus, including dengue and zika viruses, influenza, HIV; hidradenitis suppurativa (HS) and other skin diseases that cause cysts; cancers, including lung cancer metastases, pancreatic cancer, stomach cancer, myelodysplastic syndrome, leukemia; polymyositis; stroke; myocardial infarction; Grafting against host disease; hypertension; colitis; helminth infection; bacterial infection; abdominal aortic aneurysm; wound healing; depression, psychological stress; pericarditis, including Dressler syndrome, ischemia reperfusion injury, and any disease in which an individual is found to carry a germline or somatic non-silent mutation in NLRP3. 20. Spoj ili farmaceutski prihvatljiva sol ili solvat prema bilo kojem od zahtjeva 1 do 16, naznačen time, da se koristi za dijagnosticiranje bolesti, poremećaja ili stanja kod sisavaca, uključujući korak davanja obilježenog spoja prema bilo kojem od zahtjeva 1 do 16., ili njihova farmaceutski prihvatljiva sol ili solvat, ili njegov kompleks helata metalnih iona, sisavcu ili biološkom uzorku dobivenom od sisavca radi olakšavanja dijagnoze bolesti, poremećaja ili stanja sisavca.20. A compound or a pharmaceutically acceptable salt or solvate according to any one of claims 1 to 16, characterized in that it is used to diagnose a disease, disorder or condition in a mammal, including the step of administering a labeled compound according to any one of claims 1 to 16, or a pharmaceutically acceptable salt or solvate thereof, or a metal ion chelate complex thereof, to a mammal or a biological sample obtained from the mammal to facilitate the diagnosis of a disease, disorder or condition of the mammal.
HRP20211225TT 2015-02-16 2021-07-29 SULPHONILUREAS AND RELATED COMPOUNDS AND THEIR USE HRP20211225T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2015900507A AU2015900507A0 (en) 2015-02-16 Sulfonylureas and related compounds and use of same
EP19187141.7A EP3578547B1 (en) 2015-02-16 2016-02-16 Sulfonylureas and related compounds and use of same

Publications (1)

Publication Number Publication Date
HRP20211225T1 true HRP20211225T1 (en) 2021-11-12

Family

ID=56691944

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20200214TT HRP20200214T1 (en) 2015-02-16 2016-02-16 Sulfonylureas and related compounds and use of same
HRP20211225TT HRP20211225T1 (en) 2015-02-16 2021-07-29 SULPHONILUREAS AND RELATED COMPOUNDS AND THEIR USE

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HRP20200214TT HRP20200214T1 (en) 2015-02-16 2016-02-16 Sulfonylureas and related compounds and use of same

Country Status (30)

Country Link
US (4) US10538487B2 (en)
EP (3) EP3578547B1 (en)
JP (2) JP6929792B2 (en)
KR (2) KR102727059B1 (en)
CN (3) CN113563264A (en)
AU (3) AU2016222278B2 (en)
CA (1) CA2975192A1 (en)
CL (2) CL2017002097A1 (en)
CY (1) CY1122832T1 (en)
DK (2) DK3259253T3 (en)
ES (2) ES2881228T3 (en)
HR (2) HRP20200214T1 (en)
HU (1) HUE055755T2 (en)
IL (2) IL253661B2 (en)
LT (2) LT3578547T (en)
MA (3) MA47440B1 (en)
MD (1) MD3259253T2 (en)
ME (1) ME03737B (en)
MX (2) MX2017010528A (en)
MY (2) MY197094A (en)
NZ (1) NZ733948A (en)
PE (2) PE20221627A1 (en)
PL (2) PL3578547T3 (en)
PT (2) PT3259253T (en)
RS (2) RS62164B1 (en)
RU (1) RU2739356C2 (en)
SG (2) SG10202002599XA (en)
SI (2) SI3578547T1 (en)
SM (1) SMT202000192T1 (en)
WO (1) WO2016131098A1 (en)

Families Citing this family (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL253661B2 (en) * 2015-02-16 2024-01-01 Univ Queensland Sulfonylureas bearing a five-membered ring, and pharmaceutical compositions and uses thereof
FR3046933B1 (en) * 2016-01-25 2018-03-02 Galderma Research & Development NLRP3 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY SKIN CONDITIONS
MA44225A (en) 2016-02-16 2018-12-26 The Provost Fellows Found Scholars And The Other Members Of Board Of The College Of The Holy & Undiv SULPHONYLURIDES AND RELATED COMPOUNDS AND THEIR USE
ES2855732T3 (en) 2016-04-18 2021-09-24 Novartis Ag Compounds and compositions for treating conditions associated with NLRP activity
WO2018103583A1 (en) * 2016-12-05 2018-06-14 Zibo Anxuan Pharmaceutical Science And Technology Co., Ltd. N-hydroxy-benzene-sulfonamide derivatives and their uses thereof
EP3571187B1 (en) * 2017-01-23 2023-11-22 Genentech, Inc. Chemical compounds as inhibitors of interleukin-1 activity
GB2561540A (en) 2017-03-13 2018-10-24 Nodthera Ltd Chemical compounds
JP7072586B2 (en) * 2017-05-24 2022-05-20 ザ ユニバーシティ オブ クィーンズランド New compounds and uses
WO2018225018A1 (en) 2017-06-09 2018-12-13 Cadila Healthcare Limited Novel substituted sulfoximine compounds
WO2019008029A1 (en) * 2017-07-07 2019-01-10 Inflazome Limited Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors
CA3067410A1 (en) * 2017-07-07 2019-01-10 Inflazome Limited Novel sulfonamide carboxamide compounds
US11344543B2 (en) * 2017-07-14 2022-05-31 Innate Tumor Immunity, Inc. NLRP3 modulators
WO2019023145A1 (en) * 2017-07-24 2019-01-31 IFM Tre, Inc. Compounds and compositions for treating conditions associated with nlrp activity
CA3068836A1 (en) * 2017-07-24 2019-01-31 Novartis Inflammasome Research, Inc. Compounds and compositions for treating conditions associated with nlrp activity
GB201712282D0 (en) * 2017-07-31 2017-09-13 Nodthera Ltd Selective inhibitors of NLRP3 inflammasome
DE102017118230B4 (en) * 2017-08-10 2021-04-22 Christoph Lucks Method for analyzing and / or monitoring bridges and the corresponding system and use
WO2019034690A1 (en) 2017-08-15 2019-02-21 Inflazome Limited Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors
US11542255B2 (en) 2017-08-15 2023-01-03 Inflazome Limited Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors
US11926600B2 (en) 2017-08-15 2024-03-12 Inflazome Limited Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors
CA3071145A1 (en) * 2017-08-15 2019-02-21 Inflazome Limited Novel sulfonamide carboxamide compounds
EP3668862A1 (en) * 2017-08-15 2020-06-24 Inflazome Limited Novel sulfonamide carboxamide compounds
RU2020110366A (en) * 2017-08-15 2021-09-16 Инфлазоум Лимитед NEW COMPOUNDS OF SULFONAMIDE CARBOXAMIDES
WO2019034697A1 (en) * 2017-08-15 2019-02-21 Inflazome Limited Novel sulfonamide carboxamide compounds
WO2019043610A1 (en) 2017-08-31 2019-03-07 Cadila Healthcare Limited Novel substituted sulfonylurea derivatives
WO2019068772A1 (en) * 2017-10-03 2019-04-11 Inflazome Limited Novel compounds
PE20210050A1 (en) * 2017-11-09 2021-01-08 Inflazome Ltd NEW SULFONAMIDE CARBOXAMIDE COMPOUNDS
WO2019092172A1 (en) * 2017-11-09 2019-05-16 Inflazome Limited Novel sulfonamide carboxamide compounds
WO2019092171A1 (en) * 2017-11-09 2019-05-16 Inflazome Limited Novel sulfonamide carboxamide compounds
GB201721185D0 (en) * 2017-12-18 2018-01-31 Nodthera Ltd Sulphonyl urea derivatives
EP3759089A1 (en) * 2018-03-02 2021-01-06 Inflazome Limited Novel compounds
GB201803393D0 (en) * 2018-03-02 2018-04-18 Inflazome Ltd Novel compounds
WO2019166632A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
WO2019166629A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
US11905252B2 (en) 2018-03-02 2024-02-20 Inflazome Limited Compounds
WO2019166633A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Sulfonamide derivates as nlrp3 inhibitors
US11884645B2 (en) 2018-03-02 2024-01-30 Inflazome Limited Sulfonyl acetamides as NLRP3 inhibitors
WO2019166627A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
GB201803394D0 (en) 2018-03-02 2018-04-18 Inflazome Ltd Novel compounds
CN111867678B (en) * 2018-03-21 2023-04-28 欧拉泰克治疗有限责任公司 Methods of Treating Melanoma
GB201806578D0 (en) 2018-04-23 2018-06-06 Inflazome Ltd Novel compound
AU2019261274B2 (en) * 2018-04-23 2021-10-28 Corcept Therapeutics, Inc. Methods of preparing regioselective N-alkyl triazoles
AU2019263682A1 (en) 2018-05-04 2020-11-19 Inflazome Limited Novel compounds
CN108404117B (en) * 2018-05-29 2020-06-30 广东龙帆生物科技有限公司 Application of nucleotide-binding oligomerization domain-like receptor protein in medicament for treating Zika virus infection
JP2021529780A (en) * 2018-07-03 2021-11-04 ノバルティス アーゲー Methods of Treatment or Selection of Treatment for Subjects Resistant to TNF Inhibitors Using NLRP3 Antagonists
WO2020010143A1 (en) 2018-07-03 2020-01-09 Novartis Inflammasome Research, Inc. Nlrp modulators
WO2020010140A1 (en) * 2018-07-03 2020-01-09 Novartis Inflammasome Research, Inc. Nlrp modulators
AU2019306658A1 (en) * 2018-07-20 2021-01-07 F. Hoffmann-La Roche Ag Sulfonimidamide compounds as inhibitors of interleukin-1 activity
EP3823726A1 (en) * 2018-07-20 2021-05-26 F. Hoffmann-La Roche SA Sulfonylurea compounds as inhibitors of interleukin-1 activity
GB201902327D0 (en) 2019-02-20 2019-04-03 Inflazome Ltd Novel compounds
AU2019322546A1 (en) 2018-08-15 2021-03-04 Inflazome Limited Novel sulfonamideurea compounds
GB201817038D0 (en) * 2018-10-19 2018-12-05 Inflazome Ltd Novel processes
JP2022505525A (en) * 2018-10-24 2022-01-14 ノバルティス アーゲー Compounds and compositions for treating conditions associated with NLRP activity
EP3880673B1 (en) * 2018-11-13 2024-01-03 Novartis AG Compounds and compositions for treating conditions associated with nlrp activity
JP2022507065A (en) * 2018-11-13 2022-01-18 ノバルティス アーゲー Compounds and compositions for treating pathological conditions associated with NLRP activity
ES2957692T3 (en) * 2018-11-13 2024-01-24 Novartis Ag Compounds and compositions for the treatment of conditions associated with NLRP activity
WO2020102576A1 (en) * 2018-11-16 2020-05-22 Novartis Inflammasome Research, Inc. Compounds and compositions for treating conditions associated with nlrp activity
US20230059136A1 (en) * 2018-11-16 2023-02-23 Novartis Ag The compounds and compositions for treating conditions associated with nlrp activity
GB201819083D0 (en) 2018-11-23 2019-01-09 Inflazome Ltd Novel compounds
PH12021551692A1 (en) * 2019-01-14 2022-07-18 Zydus Lifesciences Ltd Novel substituted sulfonylurea derivatives
JP2022533287A (en) * 2019-01-22 2022-07-22 ノバルティス アーゲー Compounds and compositions for treating conditions associated with NLRP activity
AU2020211361A1 (en) * 2019-01-25 2021-08-19 NodThera Limited Carbamate derivatives and uses thereof
MX2021010098A (en) 2019-02-22 2021-09-28 Pi Industries Ltd A PROCESS FOR THE SYNTHESIS OF ANTHRANILIC DIAMIDE COMPOUNDS AND INTERMEDIATES THEREOF.
WO2020178441A1 (en) * 2019-03-06 2020-09-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Inhibitors of ngal protein
GB201905265D0 (en) 2019-04-12 2019-05-29 Inflazome Ltd Inflammasome inhibition
CN111848461A (en) * 2019-04-29 2020-10-30 苏州大学 NLRP3 inflammasome inhibitor and preparation method and application thereof
AR119731A1 (en) 2019-05-17 2022-01-05 Novartis Ag NLRP3 INFLAMASOME INHIBITORS
CN114761383A (en) * 2019-06-12 2022-07-15 诺瑟拉有限公司 Sulfonamide derivatives and uses thereof
LT3983387T (en) 2019-06-12 2024-07-25 NodThera Limited Sulfonylurea derivatives and uses thereof
US20220378801A1 (en) 2019-06-21 2022-12-01 Ac Immune Sa Novel compounds
WO2021002887A1 (en) 2019-07-02 2021-01-07 Novartis Inflammasome Research, Inc. Gut-targeted nlrp3 antagonists and their use in therapy
AU2020314186A1 (en) * 2019-07-17 2022-02-24 Zomagen Biosciences Ltd NLRP3 modulators
MX2022000646A (en) * 2019-07-17 2022-05-20 Zomagen Biosciences Ltd DERIVATIVES OF N-((1,2,3,5,6,7-HEXAHYDRO-S-INDACEN-4-IL)CARBAMOIL)-4,5,6,7- TETRAHYDROBENZOFURAN-2-SULFONAMIDE AND RELATED COMPOUNDS AS MODULATORS OF NLPR3 FOR THE TREATMENT OF MULTIPLE SCLEROSIS (MS).
US20220289766A1 (en) 2019-08-16 2022-09-15 Inflazome Limited Macrocyclic sulfonylurea derivatives useful as nlrp3 inhibitors
JP2022547882A (en) * 2019-09-06 2022-11-16 インフレイゾーム リミテッド NLRP3 inhibitor
JP2022548869A (en) * 2019-09-12 2022-11-22 カディラ・ヘルスケア・リミテッド Novel substituted sulfoximine derivatives
US20220409585A1 (en) * 2019-11-07 2022-12-29 Inflazome Limited Treatment of autoinflammatory disorders
WO2021089781A1 (en) * 2019-11-07 2021-05-14 Inflazome Limited Treatment or prevention of psychiatric brain disorders using the nlrp3 inhibitor n-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1 -isopropyl-1 h-pyrazole-3-sulfonamide
WO2021089768A2 (en) 2019-11-07 2021-05-14 Inflazome Limited Novel treatment
WO2021089776A1 (en) * 2019-11-07 2021-05-14 Inflazome Limited Treatment and prevention of a traumatic brain disorder
JP2023500925A (en) * 2019-11-07 2023-01-11 インフレイゾーム リミテッド Treatment and prevention of neuroinflammatory or inflammatory brain disease
GB201916237D0 (en) * 2019-11-07 2019-12-25 Inflazome Ltd Novel treatment
CN112851607A (en) * 2019-11-12 2021-05-28 成都百裕制药股份有限公司 Amide derivative, preparation method and medical application thereof
WO2021111351A1 (en) * 2019-12-03 2021-06-10 Cadila Healthcare Limited Novel substituted sulfonylurea and sulfoximineurea derivatives
IL294536A (en) * 2020-01-22 2022-09-01 Hoffmann La Roche Sulfonimidamide compounds as nlrp3 modulators
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
CN115362152A (en) 2020-02-18 2022-11-18 英夫拉索姆有限公司 Compound (I)
MX2022011576A (en) 2020-03-16 2022-10-18 Zomagen Biosciences Ltd Nlrp3 modulators.
CN111358778A (en) * 2020-03-17 2020-07-03 中国医科大学附属第一医院 Application of MCC950 in preparation of medicine for preventing or treating Alzheimer disease
CN115297855A (en) 2020-03-19 2022-11-04 索芙特海尔公司 Methods of treating NLRP 3-associated diseases
US20230219920A1 (en) * 2020-06-11 2023-07-13 Medshine Discovery Inc. Dimethylsulfoximine derivative
WO2021255279A1 (en) 2020-06-19 2021-12-23 Ac Immune Sa D i h yd rooxazo le and thiourea derivatives modulating the nlrp3 inflammasome pathway
WO2022022646A1 (en) * 2020-07-29 2022-02-03 南京明德新药研发有限公司 Selenium-containing five-membered heteroaromatic ring compound
WO2022023907A1 (en) 2020-07-31 2022-02-03 Novartis Ag Methods of selecting and treating patients at elevated risk of major adverse cardiac events
WO2022051582A1 (en) * 2020-09-04 2022-03-10 NodThera Limited Sulphamoyl urea derivatives containing alkyl-oxacycloalkyl moiety and uses thereof
WO2022098108A1 (en) * 2020-11-04 2022-05-12 (주) 업테라 Nlrp3 protein degradation inducing compound
FR3115682B1 (en) * 2020-11-05 2023-02-24 Roquette Freres Compositions based on methyl-cyclodextrins for the treatment and/or prevention of hepatic steatosis
TW202237577A (en) * 2020-11-20 2022-10-01 美商戴納立製藥公司 Compounds, compositions, and methods
EP4251630A4 (en) * 2020-11-25 2024-12-11 Venatorx Pharmaceuticals, Inc. SULFONYL UREA NRLRP3 INFLAMMA SUMMER INHIBITOR
KR102802013B1 (en) * 2021-02-03 2025-05-07 환인제약 주식회사 Small Molecule Inhibitors of NLRP3 Inflammasome for Treatment of Alzheimer's Disease
JP2024508728A (en) * 2021-02-10 2024-02-28 ハンジョウ イノゲート ファーマ カンパニー リミテッド Compounds as NLRP3 inhibitors
US11319319B1 (en) 2021-04-07 2022-05-03 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
IT202100011237A1 (en) * 2021-05-03 2022-11-03 Univ Degli Studi Di Torino NLRP3 INFLAMMASOME INHIBITOR COMPOUNDS AND THEIR USE
WO2022237782A1 (en) * 2021-05-10 2022-11-17 成都百裕制药股份有限公司 Amide derivative and application thereof
WO2022237780A1 (en) * 2021-05-10 2022-11-17 成都百裕制药股份有限公司 Amide derivative and use thereof
TWI815439B (en) * 2021-05-10 2023-09-11 大陸商成都百裕製藥股份有限公司 Amide derivatives and applications thereof
JP2024524250A (en) 2021-06-23 2024-07-05 エフ． ホフマン－ラ ロシュ アーゲー Crystalline potassium salt of 1-ethyl-N-((1,2,3,5,6,7-hexahydro-S-indacen-4-yl)carbamoyl)piperidine-4-sulfonamide
ES2948511A1 (en) * 2021-09-08 2023-09-13 Fundacion Para La Investigacion Biomedica Del Hospital Univ De La Princesa N-SULFONYLUREA DERIVATIVES AND THEIR THERAPEUTIC USE (Machine-translation by Google Translate, not legally binding)
CN115894478B (en) * 2021-09-30 2025-04-04 杭州民生药物研究院有限公司 A novel pyridopyrazole heterocyclic compound and its application
KR20230066899A (en) 2021-11-08 2023-05-16 제일약품주식회사 Novel compounds as nlrp3 inhibitor and pharmaceutical composition comprising the same
CN118355000A (en) * 2021-12-03 2024-07-16 辰欣药业股份有限公司 Salt and crystal forms of dimethyl sulfimide derivative
WO2023118521A1 (en) 2021-12-22 2023-06-29 Ac Immune Sa Dihydro-oxazol derivative compounds
WO2023230002A1 (en) * 2022-05-23 2023-11-30 VenatoRx Pharmaceuticals, Inc. Nlrp3 inflammasome inhibitors
EP4551549A1 (en) * 2022-07-06 2025-05-14 Kodiak Sciences Inc. Nlrp3 inhibitors
WO2024013395A1 (en) 2022-07-14 2024-01-18 Ac Immune Sa Pyrrolotriazine and imidazotriazine derivatives as modulators of the nlrp3 inflammasome pathway
US20240101563A1 (en) 2022-07-28 2024-03-28 Ac Immune Sa Novel compounds
KR20240022938A (en) 2022-08-12 2024-02-20 제일약품주식회사 Novel compounds as nlrp3 inhibitor and pharmaceutical composition comprising the same
US12331048B2 (en) 2022-10-31 2025-06-17 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
CN115772173B (en) * 2022-12-20 2024-04-16 武汉国粹医药科技有限公司 Benzofuran compound, preparation method and application thereof, and antibacterial agent
TW202502344A (en) 2023-06-02 2025-01-16 美商默沙東有限責任公司 5,6 unsaturated bicyclic heterocyles useful as inhibitors of nod-like receptor protein 3
WO2025046419A1 (en) 2023-08-25 2025-03-06 제일약품주식회사 Novel compound as nlrp3 inhibitor and pharmaceutical composition comprising same
WO2025068958A1 (en) * 2023-09-29 2025-04-03 Novartis Ag Nlrp3 inhibitor for use in lowering the risk of cardiovascular diseases
WO2025133307A1 (en) 2023-12-22 2025-06-26 Ac Immune Sa Heterocyclic modulators of the nlrp3 inflammasome pathway

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB797474A (en) 1955-07-20 1958-07-02 Boehringer & Soehne Gmbh Sulphonylurea derivatives
US3242174A (en) 1962-02-06 1966-03-22 Pfizer & Co C 1-(tertiary aminosulfonyl)-3-(hydrocarbon) ureas
US3305556A (en) 1962-11-23 1967-02-21 Pfizer & Co C Novel hypoglycemic agents
NL129208C (en) 1965-07-14
CH509992A (en) 1966-08-08 1971-07-15 Hoffmann La Roche Process for the preparation of sulfonamides
NL131473C (en) 1966-10-28
BE754588A (en) 1969-08-07 1971-02-08 Hoechst Ag THIOPHENE-SULFONYL-UREES AND THE MEDICINAL PRODUCTS CONTAINING THESE SUBSTANCES
FR2063472A5 (en) 1969-10-17 1971-07-09 Mercier Pierre
GB1477664A (en) * 1974-04-17 1977-06-22 Christiaens Sa A Pyridine derivatives
AU571869B2 (en) 1983-05-09 1988-04-28 E.I. Du Pont De Nemours And Company Pyridyl- and pyrimidyl- sulphonamides
EP0126711B1 (en) 1983-05-16 1989-08-02 Ciba-Geigy Ag Herbicidally active and plant growth regulating pyrimidine derivatives, their preparation and use
JPS6045573A (en) 1983-08-22 1985-03-12 Nissan Chem Ind Ltd Pyrazolesulfonylurea derivative, its preparation and selective herbicide containing said derivative
US4723991A (en) 1984-03-23 1988-02-09 E. I. Du Pont De Nemours And Company Lower alkyl 2-[[N-(3-cyano-pyridin-2-yl)aminocarbonyl]aminosulphonyl]benzoate derivatives having herbicidal activity
US4659369A (en) 1984-08-27 1987-04-21 E. I. Du Pont De Nemours And Company Herbicidal acetals and ketals
AU578307B2 (en) 1984-09-17 1988-10-20 E.I. Du Pont De Nemours And Company Herbicidal pyrazolesulfonamides
FI855180L (en) 1985-01-18 1986-07-19 Nissan Chemical Ind Ltd PYRAZOLSULFONAMID DERIVATIVES, FOERFARANDE FOER DESS FRAMSTAELLANDE OCH DET INNEHAOLLANDE OGRAESGIFT.
JPH0720957B2 (en) 1985-11-26 1995-03-08 日産化学工業株式会社 Pyrazole sulfonylurea derivative, process and herbicide
JP2570686B2 (en) 1985-12-23 1997-01-08 日産化学工業株式会社 Pyrazole derivatives
US4830660A (en) 1986-06-19 1989-05-16 Nissan Chemical Industries, Ltd. Imidazolesulfonamide derivatives and herbicides
US4795486A (en) 1986-09-26 1989-01-03 Boehner Beat Aminopyrazinones and aminotriazinones
US4802908A (en) 1987-01-22 1989-02-07 E. I. Du Pont De Nemours And Company Herbicidal 2-(1H)-pyrazinones
AU7165591A (en) 1990-01-22 1991-08-05 E.I. Du Pont De Nemours And Company Herbicidal sulfonylureas
IL98784A0 (en) 1990-07-17 1992-07-15 Lilly Co Eli Heterocyclyl sulfonamide derivatives,process for their preparation and pharmaceutical compositions containing them
CA2089765A1 (en) 1990-08-29 1992-03-01 William Thomas Zimmerman Herbicidal pyrrolesulfonylureas
US5214206A (en) * 1990-11-07 1993-05-25 Warner-Lambert Company Aminosulfonyl urea acat inhibitors
DE4039733A1 (en) 1990-12-13 1992-06-17 Basf Ag SUBSTITUTED 5-AMINOPYRAZOLE
WO1993004046A1 (en) 1991-08-19 1993-03-04 E.I. Du Pont De Nemours And Company Angiotensin ii receptor blocking imidazolinone derivatives
CZ36294A3 (en) 1991-08-19 1994-07-13 Du Pont Substituted imidazilonone derivatives and pharmaceutical preparations based thereon
US5169860A (en) * 1992-03-13 1992-12-08 Eli Lilly And Company Antitumor compositions and methods of treatment
US5219856A (en) 1992-04-06 1993-06-15 E. I. Du Pont De Nemours And Company Angiotensin-II receptor blocking, heterocycle substituted imidazoles
JPH0645573A (en) 1992-07-23 1994-02-18 Nikon Corp Infrared ray solid-state image pick-up device
JPH06199053A (en) 1992-12-28 1994-07-19 Sankyo Kagaku Kk Color element for heat transfer recording
JPH06199054A (en) 1992-12-28 1994-07-19 Dainippon Printing Co Ltd Heat transfer sheet
JPH06199047A (en) 1993-01-08 1994-07-19 New Oji Paper Co Ltd Heat-sensitive recording substance
US5466823A (en) * 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
AU7007696A (en) 1995-09-22 1997-04-09 E.I. Du Pont De Nemours And Company Arthropodicidal 1,4-dihydropyridines and 1,4-dihydropyrimidines
EP0795548B1 (en) 1995-09-28 2002-07-03 Suntory Limited Quinazoline derivatives and use thereof
WO1997030978A1 (en) 1996-02-26 1997-08-28 Sumitomo Pharmaceuticals Company, Limited Sulfonylureidopyrazole derivatives
CA2279186C (en) * 1997-01-29 2004-02-24 Pfizer Inc. Sulfonyl urea derivatives and their use in the control of interleukin-1 activity
US6022984A (en) 1998-07-27 2000-02-08 Pfizer Inc. Efficient synthesis of furan sulfonamide compounds useful in the synthesis of new IL-1 inhibitors
JP2000053649A (en) 1998-08-11 2000-02-22 Sumitomo Pharmaceut Co Ltd Sulfonylureidopyrazole derivatives
EP0987552A3 (en) * 1998-08-31 2000-06-07 Pfizer Products Inc. Diarylsulfonylurea binding proteins
CZ20013248A3 (en) 1999-03-15 2002-04-17 Axys Pharmaceuticals, Inc. Novel compounds and preparations functioning as protease inhibitors
BR0014003A (en) * 1999-09-14 2002-05-21 Pfizer Prod Inc Combination treatment with compounds of diaryl sufonil urea and il-1ra
JP4574100B2 (en) 2000-02-04 2010-11-04 ポートラ ファーマシューティカルズ， インコーポレイテッド Platelet ADP receptor inhibitor
US6906063B2 (en) 2000-02-04 2005-06-14 Portola Pharmaceuticals, Inc. Platelet ADP receptor inhibitors
GB0017676D0 (en) 2000-07-19 2000-09-06 Angeletti P Ist Richerche Bio Inhibitors of viral polymerase
CA2369967A1 (en) * 2001-02-12 2002-08-12 Joseph Anthony Cornicelli Methods of treating nuclear factor-kappa b mediated diseases and disorders
WO2002094176A2 (en) 2001-05-18 2002-11-28 Solvay Pharmaceuticals Gmbh Use of compounds with combined nep/mp-inhibitory activity on the preparation of medicaments
AR037097A1 (en) 2001-10-05 2004-10-20 Novartis Ag ACILSULFONAMID COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND THE USE OF SUCH COMPOUNDS FOR THE PREPARATION OF A MEDICINAL PRODUCT
FI110677B (en) 2001-10-12 2003-03-14 Jujo Thermal Oy Heat-sensitive recording material for use in, e.g. stickers, has coating layer comprising chelate-type color forming system and leuco dye with urea-based developer
JP4351053B2 (en) 2001-10-26 2009-10-28 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー Dihydroxypyrimidine carboxamide HIV integrase inhibitor
CA2468706A1 (en) 2001-11-30 2003-06-05 Mark Anthony Dombroski Combination of an il-1/18 inhibitor with a tnf inhibitor for the treatment of inflammation
AR039891A1 (en) 2002-05-28 2005-03-09 Dimensional Pharm Inc THIOPHEN-AMIDINE COMPOUNDS, THEIR PHARMACEUTICAL COMPOSITIONS AND THEIR USE FOR THE PREPARATION OF MEDICINES TO TREAT DISEASES AND DISORDERS MEDIATED BY C1S
WO2005032488A2 (en) 2003-10-03 2005-04-14 Portola Pharmaceuticals, Inc. 2,4-dioxo-3-quinazolinylaryl sulfonylureas
JP4879745B2 (en) 2003-10-03 2012-02-22 ポートラ ファーマシューティカルズ， インコーポレイテッド Substituted isoquinolinone
WO2005105777A1 (en) * 2004-05-05 2005-11-10 Pharmacia & Upjohn Company Llc Substituted thiophene amide compounds for the treatment of inflammation
KR20070064356A (en) 2004-09-29 2007-06-20 포톨라 파마슈티컬스, 인코포레이티드 Substituted 2H-1,3-benzoxazine-4 (3H) ones
WO2006085815A1 (en) 2005-02-11 2006-08-17 Astrazeneca Ab Thiazole derivatives, their process for their preparation and their use in therapy
GB0505539D0 (en) 2005-03-17 2005-04-27 Novartis Ag Organic compounds
DK200600313A (en) 2006-03-03 2006-03-13 Novo Nordisk As Treating type 2 diabetes or metabolic syndrome with an interleukin 1beta inhibitor or an interleukin 1beta synthesis or release inhibitor
RU2008140144A (en) * 2006-03-10 2010-04-20 Оно Фармасьютикал Ко., Лтд. (Jp) NITROGEN CONTAINING HETEROCYCLIC DERIVATIVE AND PHARMACEUTICAL PRODUCT INCLUDING SUCH DERIVATIVE AS AN ACTIVE INGREDIENT
TWI391378B (en) 2006-03-16 2013-04-01 Astellas Pharma Inc Quinolone derivative or pharmaceutically acceptable salt thereof
GB0701426D0 (en) 2007-01-25 2007-03-07 Univ Sheffield Compounds and their use
US8486987B2 (en) 2007-11-16 2013-07-16 University Of Medicine And Dentistry Of New Jersey Mechanism-based small-molecule parasite inhibitors
US8211928B2 (en) * 2009-05-29 2012-07-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
GB2474120B (en) 2009-10-01 2011-12-21 Amira Pharmaceuticals Inc Compounds as Lysophosphatidic acid receptor antagonists
US8815874B2 (en) 2010-03-05 2014-08-26 Kyowa Hakko Kirin Co., Ltd. Pyrazolopyrimidine derivative
JP5924742B2 (en) 2010-11-18 2016-05-25 国立大学法人京都大学 Screening for drugs that suppress inflammasome activity
CN104023729A (en) 2011-09-02 2014-09-03 协和发酵麒麟株式会社 Chemokine receptor activity regulator
JP6036193B2 (en) 2012-11-09 2016-11-30 国立大学法人富山大学 Inflammasome activity regulator
PL221813B1 (en) 2013-02-22 2016-05-31 Univ Medyczny W Lublinie Derivatives of 1-aryl-6-benzenesulfonylimidazo[1,2-a][1.3.5]triazine and their preparation
TW201501713A (en) 2013-03-01 2015-01-16 Kyowa Hakko Kirin Co Ltd Agent for preventing and/or treating ocular inflammatory disease
CN104513239B (en) 2014-12-10 2017-08-22 沈阳药科大学 The ketone compounds of pyrazolo [3,4 c] pyridine 7 and its application
WO2016119349A1 (en) 2015-01-29 2016-08-04 中国农业大学 Preparation method for sulfonylurea and sulfonamide formate compounds
IL253661B2 (en) * 2015-02-16 2024-01-01 Univ Queensland Sulfonylureas bearing a five-membered ring, and pharmaceutical compositions and uses thereof
WO2016138473A1 (en) 2015-02-26 2016-09-01 H. Lee Moffitt Cancer Center And Research Institute, Inc. Inflammasome activation in myelodysplastic syndromes
CA3008909C (en) 2015-12-23 2023-10-03 The University Of British Columbia Lipid-linked prodrugs
FR3046933B1 (en) 2016-01-25 2018-03-02 Galderma Research & Development NLRP3 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY SKIN CONDITIONS
MA44225A (en) 2016-02-16 2018-12-26 The Provost Fellows Found Scholars And The Other Members Of Board Of The College Of The Holy & Undiv SULPHONYLURIDES AND RELATED COMPOUNDS AND THEIR USE
JP7041668B2 (en) 2016-04-18 2022-03-24 ノバルティス アーゲー Compounds and compositions for treating conditions associated with NLRP activity
US10080742B2 (en) 2016-04-26 2018-09-25 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
WO2017189663A1 (en) 2016-04-26 2017-11-02 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
US10080741B2 (en) 2016-04-26 2018-09-25 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
US10138228B2 (en) 2016-05-18 2018-11-27 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use therof
US10144729B2 (en) 2016-05-18 2018-12-04 Enanta Pharmaceuticals, Inc. Isoxazole analogs as FXR agonists and methods of use thereof
JP7072586B2 (en) 2017-05-24 2022-05-20 ザ ユニバーシティ オブ クィーンズランド New compounds and uses
WO2019008029A1 (en) 2017-07-07 2019-01-10 Inflazome Limited Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors
CA3067410A1 (en) 2017-07-07 2019-01-10 Inflazome Limited Novel sulfonamide carboxamide compounds
RU2020110366A (en) 2017-08-15 2021-09-16 Инфлазоум Лимитед NEW COMPOUNDS OF SULFONAMIDE CARBOXAMIDES
EP3827530B1 (en) 2018-09-27 2023-05-10 Apple Inc. Radio link monitoring and failure for new radio-unlicensed operation
GB201819083D0 (en) * 2018-11-23 2019-01-09 Inflazome Ltd Novel compounds

Also Published As

Publication number Publication date
RU2017128287A3 (en) 2019-08-01
SG10202002599XA (en) 2020-04-29
IL253661A0 (en) 2017-09-28
US20220112159A1 (en) 2022-04-14
PL3259253T3 (en) 2020-09-07
ES2777626T3 (en) 2020-08-05
CA2975192A1 (en) 2016-08-25
US20240400502A1 (en) 2024-12-05
PT3578547T (en) 2021-06-22
RU2739356C2 (en) 2020-12-23
US11130731B2 (en) 2021-09-28
CN113563264A (en) 2021-10-29
AU2020203464A1 (en) 2020-06-18
DK3578547T3 (en) 2021-08-23
PL3578547T3 (en) 2021-12-20
RU2017128287A (en) 2019-03-18
HUE055755T2 (en) 2021-12-28
SG11201706664QA (en) 2017-09-28
NZ733948A (en) 2022-02-25
MA41553B1 (en) 2020-04-30
WO2016131098A1 (en) 2016-08-25
AU2016222278A1 (en) 2017-08-10
CY1122832T1 (en) 2021-05-05
SI3259253T1 (en) 2020-07-31
CN113582889A (en) 2021-11-02
KR102727059B1 (en) 2024-11-05
EP3259253A4 (en) 2018-07-25
MY197094A (en) 2023-05-24
JP7566699B2 (en) 2024-10-15
EP3578547B1 (en) 2021-05-26
ME03737B (en) 2021-01-20
AU2016222278B2 (en) 2020-07-09
PE20221627A1 (en) 2022-10-19
MA41553A (en) 2017-12-27
PE20180160A1 (en) 2018-01-18
EP3888749A1 (en) 2021-10-06
SI3578547T1 (en) 2021-09-30
US10538487B2 (en) 2020-01-21
CN107428696A (en) 2017-12-01
KR20240162585A (en) 2024-11-15
MA56473A (en) 2022-05-11
AU2021258033A1 (en) 2021-11-25
JP2021185159A (en) 2021-12-09
MA47440A (en) 2019-12-11
CL2017002097A1 (en) 2018-04-27
NZ772349A (en) 2024-02-23
IL273065B2 (en) 2024-01-01
HRP20200214T1 (en) 2020-08-07
EP3259253A1 (en) 2017-12-27
IL253661B2 (en) 2024-01-01
US20190359564A1 (en) 2019-11-28
PT3259253T (en) 2020-03-11
BR112017017610A2 (en) 2018-05-08
CN107428696B (en) 2021-08-20
EP3578547A1 (en) 2019-12-11
JP6929792B2 (en) 2021-09-01
MD3259253T2 (en) 2020-06-30
WO2016131098A8 (en) 2017-03-16
MY193765A (en) 2022-10-27
AU2020203464B2 (en) 2021-08-05
LT3578547T (en) 2021-08-25
IL273065B1 (en) 2023-09-01
CN113582889B (en) 2024-09-20
HK1249501A1 (en) 2018-11-02
RS60048B1 (en) 2020-04-30
RS62164B1 (en) 2021-08-31
MA47440B1 (en) 2021-08-31
CL2019000060A1 (en) 2019-05-03
IL273065A (en) 2020-04-30
JP2018510207A (en) 2018-04-12
KR20170109678A (en) 2017-09-29
MX2017010528A (en) 2018-11-12
LT3259253T (en) 2020-04-27
SMT202000192T1 (en) 2020-05-08
MX2023001647A (en) 2023-03-16
EP3259253B1 (en) 2020-01-15
US20180044287A1 (en) 2018-02-15
DK3259253T3 (en) 2020-04-14
IL253661B1 (en) 2023-09-01
ES2881228T3 (en) 2021-11-29

Similar Documents

Publication Publication Date Title
HRP20211225T1 (en) SULPHONILUREAS AND RELATED COMPOUNDS AND THEIR USE
JP2018510207A5 (en)
ES2927777T3 (en) Compounds and compositions for the treatment of conditions associated with NLRP activity
ES2828733T3 (en) Imidazopyridazine compounds useful as modulators of responses to IL-12, IL-23 and / or IFN alpha
HRP20231690T1 (en) Selective inhibitors of nlrp3 inflammasome
HRP20210472T1 (en) Bicyclic-fused heteroaryl or aryl compounds as irak4 modulators
JP2020505381A5 (en)
HRP20240355T1 (en) 8-cyano-5-piperidino-quinolines as tlr7/8 antagonists and their uses for treating immune disorders
HRP20180335T1 (en) Fused imidazole derivatives useful as ido inhibitors
HRP20210413T1 (en) N-(6-((2r,3s)-3,4-dihydroxybutan-2-yloxy)-2-(4-fluorobenzylthio)pyrimidin-4-yl)-3- methylazetidine-1-sulfonamide as chemokine receptor modulator
ES2849974T3 (en) Imidazopyridazine modulators of IL-12, IL-23 and / or IFNalpha
HRP20200179T1 (en) Heteroaryl compounds as irak inhibitors and uses thereof
HRP20191579T1 (en) Compounds as modulators of ror gamma
RU2017134551A (en) NEW DIHYDROPYRIDOISOCHINOLINONES AND THEIR PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF INFLAMMATORY DISORDERS
JP2017525737A5 (en)
IL294536A (en) Sulfonimidamide compounds as nlrp3 modulators
HRP20240896T1 (en) Sulfonylurea derivatives and uses thereof
CN114981262A (en) Heteroaryl compounds and their preparation methods and uses
JP2024525561A (en) Compounds, Compositions and Methods
JP2023532298A (en) Compounds, compositions and methods
AU2023245337A1 (en) Compounds, compositions, and methods
NZ772349B2 (en) Sulfonylureas and related compounds and use of same
RU2019126388A (en) CHEMICAL COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY
RU2021103834A (en) SULFONYLUREA COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY
JPWO2022051582A5 (en)